Fecal Microbiota Transplant for Neuroblastoma in a Single Patient

N/ANo Longer AvailableNCT07223606

ProgenaBiome

Overview

This study uses fecal microbiota transplant (FMT) to correct gut microbiome dysbiosis prior to and during standard-of-care neuroblastoma treatment

Patients with neurobastoma and concurrent dysbiosis showing a bifidobacteria-bacteroides gap will undergo fecal microbiota transplant as an adjunctive to standard-of-care oncology treatment.

Study Type

EXPANDED_ACCESS

Conditions

Neuroblastoma Neuroblastoma (NB)Neuroblastoma (NBL)Neuroblastoma (Measurable Disease)Neuroblastoma Recurrent Neuroblastoma in Children Neuroblastoma. CNS

Interventions

Fecal Microbial TransplantationBIOLOGICAL

This study will utilize donor stool from an infant

Eligibility

Sex: ALLMin age: 5 Years

Medical Language ↔ Plain English

Inclusion Criteria: * willingness of parent/guardian to sign ICF * diagnosis of neuroblastoma * dysbiosis of the gut microbiome Exclusion Criteria: * parent/guardian unwilling to sign ICF * dysbiosis does not show a bifidobaceteria-bacteroides gap * severely abnormal screening lab values

Locations (1)

ProgenaBiome

Ventura, California, United States

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.